Boehringer Ingelheim Pharmaceuticals reports that it has received final approval from the Food and Drug Administration for its Pradaxa (dabigatran etexilate mesylate) to be used to prevent deep vein thrombosis or pulmonary embolism in patients who have had hip replacement surgery. The approval is for a new use for the drug, which was launched in 2010.